Please assess the completion status of the following clinical trial:

Trial Title: BATTLE Trial: Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~* Patient ≥18 years~* Patient has a history of symptomatic peripheral arterial disease (Rutherford classification: 2-5)~* Lesion is eligible for treatment with a maximum of 2 stents per lesion (treatment of both legs is not permitted)~* Patient is affiliated to the Social Security or equivalent system~* Patient has been informed of the nature of the study, agrees to its provisions (and only for swiss centers, has signed the informed consent form prior to any study related procedure)~* Patient agrees to undergo all protocol required follow-up examinations and requirements at the investigational site~* Reference vessel diameter 4 to 7-mm determined by CT scan (RVD obtained from averaging 5-mm segments proximal and distal to the lesions)~* Target lesion has a pre-procedure percent diameter stenosis of ≥ 50% DS~* De novo atherosclerotic lesions (stenosis and/or occlusion) of the superficial femoral artery, the proximal popliteal artery (P1), or both. The treatment area in the SFA and popliteal artery extended from 1 cm below the origin of the profunda femoris artery to 3 cm above the proximal margin of the intercondylar fossa of the femur.~* Target lesion (single or multiple) has a maximal total length =14-cm and a minimal length = 2-cm~* At least 1 patent runoff vessel (\<50% DS throughout its course). The inflow artery(ies) cannot be treated using a drug eluting stent or drug coated balloon.~Exclusion Criteria~* Asymptomatic lesion~* Restenosis~* No atheromatous disease~* Untreated \>50% DS of the inflow tract~* Resting ankle brachial index (ABI) unavailable~* Female of child bearing potential~* Patient has received, or is on the waiting list for a major organ transplant~* Patient has a history of coagulopathy or will refuse blood transfusions~* Patient is receiving or scheduled to receive anticancer therapy for malignancy within 1 year prior to or after the procedure~* Severe concomitant disease with life expectation \< one year~* Known allergy to paclitaxel~* Contraindication to Aspirin or Clopidogrel and Ticlopidin (the patient must be able to receive Dual Anti-Platelet Treatment for 2 months after the procedure)~* Patient has an infected wound or osteomyelitis on the ipsilateral extremity or foot.~* Patient has had prior major amputation to the ipsilateral (target) extremity~* Patient is not able to give informed consent (and only for swiss centers)~* Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints Note: Trials requiring extended follow-up for products that were investigational, but have become commercially available since then, are not considered investigational trials~* Patient has previously had, or requires, bypass surgery, endarterectomy or other vascular surgery on any vessel of the ipsilateral extremity~* In the Investigator's opinion patient has (a) co-morbid condition(s) that could limit the patient's ability to participate in the study, compliance with follow-up requirements or impact the scientific integrity of the study~* Target lesion lies within or adjacent to an aneurysm~* Patient with an allergy to contrast agent~* Patient with a severe allergy to metal~* Surgery or endovascular intervention of the target member within 14 days preceding the BATTLE procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Misago RX (Misago RX, Terumo Corp., Tokyo (Type: OTHER): The Misago RX is a peripheral stent (Misago RX, Terumo Corp., Tokyo, Japan) indicated to treat iliac and femoropopliteal arteries. The Misago RX is a flexible self-expanding nitinol stent that is delivered via a RX monorail delivery catheter.
- Zilver PTX (Cook Medical, Bloomington, IN, USA) (Type: OTHER): Zilver PTX (Cook Medical, Bloomington, IN, USA) is a nitinol stent with a polymer-free paclitaxel coating designed to treat the above- the-knee femoropopliteal arteries. The anti-proliferative drug is the paclitaxel, a cytotoxic drug. The Zilver PTX stent is delivered via a over-the-wire system.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy